X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xiamen Amoytop Biotech Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
EPS (Diluted)
ÂĄ1
CAGR 3-Years
68%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
EPS (Diluted)
-ÂĄ4
CAGR 3-Years
17%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-5%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
EPS (Diluted)
ÂĄ0
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
16%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
EPS (Diluted)
ÂĄ2
CAGR 3-Years
-18%
CAGR 5-Years
16%
CAGR 10-Years
33%
Imeik Technology Development Co Ltd
SZSE:300896
EPS (Diluted)
ÂĄ6
CAGR 3-Years
35%
CAGR 5-Years
52%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's EPS (Diluted)?
EPS (Diluted)
1.4 CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's EPS (Diluted) amounts to 1.4 CNY.

What is Xiamen Amoytop Biotech Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
103%

Over the last year, the EPS (Diluted) growth was 93%. The average annual EPS (Diluted) growth rates for Xiamen Amoytop Biotech Co Ltd have been 68% over the past three years , 103% over the past five years .

Back to Top